Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
Clin Radiol ; 75(2): 123-130, 2020 02.
Article in English | MEDLINE | ID: mdl-31676038

ABSTRACT

AIM: To investigate the diagnostic performance of proton density fat fraction (PDFF) and simultaneous R2* for focal vertebral bone marrow lesion (VBML) assessment, compared with the apparent diffusion coefficient (ADC). MATERIALS AND METHODS: One hundred and ninety-two spinal magnetic resonance imaging (MRI) examinations performed in 126 patients with focal VBMLs from March 2016 to November 2018 were reviewed retrospectively. The lesions were divided into metastases and benign VBMLs. The protocol consisted of routine morphological MRI sequences, followed by complex-based chemical shift imaging (CSE)-MRI and diffusion-weighted (DW)-MRI with a 1.5 T system. PDFF, R2*, and the ADC values were compared using the Mann-Whitney U-test. Receiver operating characteristic curve analysis was carried out to assess the diagnostic performance for differentiating metastases from focal benign VBMLs. RESULTS: PDFF, R2*, and mean ADC values in metastases were significantly lower than those in benign VBMLs (p<0.05). The PDFF (area under the curve [AUC]= 0.968; 95% confidence interval [CI]=0.932-0.988) showed a significantly larger AUC compared with R2* (AUC=0.670; 95% CI=0.599-0.736) and ADC (AUC=0.801; 95% CI=0.738-0.855). The optimal cut-off value of the PDFF for predicting metastases was 9%; this threshold corresponded to a sensitivity of 96.67%, specificity of 90.28%, and accuracy of 94.27%. CONCLUSION: PDFF is significantly more accurate than ADC and R2* for differentiating focal benign VMBLs from metastases.


Subject(s)
Bone Marrow/diagnostic imaging , Spine/diagnostic imaging , Adult , Aged , Aged, 80 and over , Bone Marrow Diseases/diagnostic imaging , Diffusion Magnetic Resonance Imaging , Female , Humans , Magnetic Resonance Imaging , Magnetic Resonance Spectroscopy , Male , Middle Aged , ROC Curve , Retrospective Studies , Spinal Neoplasms/diagnostic imaging , Spinal Neoplasms/secondary , Young Adult
2.
Ann Oncol ; 27(3): 494-501, 2016 Mar.
Article in English | MEDLINE | ID: mdl-26673353

ABSTRACT

BACKGROUND: This study explored the prognostic impact of tumor-infiltrating lymphocytes (TILs) and investigated whether three histologic subtypes (lymphoepithelioma-like carcinoma, carcinoma with Crohn's disease-like lymphoid reaction, and conventional-type adenocarcinoma) could stratify a prognostic subset for patients with Epstein-Barr virus (EBV)-associated gastric cancer (EBVaGC). MATERIALS AND METHODS: After reviewing 1318 consecutive cases of surgically resected or endoscopic submucosal dissected gastric cancers, 120 patients were identified as EBV-positive using EBV-encoded RNA in situ hybridization. The evaluation of the percentage of intratumoral (iTu-) and stromal (str-) TILs was carried out, and the cases were also subclassified into three histologic subtypes as noted above. RESULTS: Among the 120 patients, 73 patients (60.8%) and 60 patients (50.0%) were determined as str-TIL-positive and iTu-TIL-positive, respectively. In a univariate analysis, str-TIL-positivity was significantly associated with longer recurrence-free survival (RFS; P = 0.002) and disease-free survival (DFS; P = 0.008), yet not overall survival (OS; P = 0.145). While iTu-TIL-positivity has a tendency of favorable outcome indicator for DFS and OS, but statistically significant differences were not shown, respectively (RFS, P = 0.058; DFS, P = 0.151; OS, P = 0.191). In a multivariate analysis using a Cox proportional hazard model adjusted for age, pTNM stage, lymphatic invasion, perineural invasion, and venous invasion; histologic subtype, WHO classification, and str-TIL-positivity were independently or tentatively associated with favorable RFS (hazard ratio [HR] = 12.193, 95% confidence interval [95% CI] 1.039-143.055, P = 0.047) or DFS (HR = 4.836, 95% CI 0.917-25.525, P = 0.063). CONCLUSION: The histologic subclassification and TILs can be used to predict RFS and DFS for patients with EBVaGC.


Subject(s)
Adenocarcinoma/virology , Epstein-Barr Virus Infections/immunology , Herpesvirus 4, Human/immunology , Lymphocytes, Tumor-Infiltrating/immunology , Stomach Neoplasms/virology , Adenocarcinoma/mortality , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Adult , Aged , Aged, 80 and over , Biomarkers, Tumor , Disease-Free Survival , Epstein-Barr Virus Infections/virology , Female , Herpesvirus 4, Human/genetics , Humans , Lymphocytes, Tumor-Infiltrating/pathology , Male , Middle Aged , Proportional Hazards Models , Stomach Neoplasms/mortality , Stomach Neoplasms/pathology , Stomach Neoplasms/therapy , Treatment Outcome
4.
Aliment Pharmacol Ther ; 39(6): 609-18, 2014 Mar.
Article in English | MEDLINE | ID: mdl-24461252

ABSTRACT

BACKGROUND: Whether the incidence of metachronous gastric dysplasia and cancer could be decreased by eradication of Helicobacter pylori after endoscopic submucosal dissection (ESD) for early gastric cancer (EGC). AIM: To compare the incidence of metachronous gastric lesion in the eradicated group and the persistent group. Second end point is to evaluate the risk factors for metachronous gastric lesions after ESD for EGC. METHODS: In a single centre, between May 2007 and May 2010, the patients who had evidence of H. pylori infection at the time of ESD for EGC were included, and the follow-up data were analysed retrospectively. RESULTS: We enrolled 283 patients who have shown H. pylori infection at the time of ESD for EGC. Successful eradication was achieved for 214 patients (75.6%) (Eradicated group), and 69 patients (24.4%) showed persistent H. pylori infection (Persistent group). Metachronous gastric lesions developed in 13 (18.8%) in the persistent group and 18 (8.4%) in the eradicated group (P = 0.016). In the ≥60-year-old group, the cumulative incidence of metachronous gastric cancer showed a significant increase (P = 0.012). Cumulative hazard ratio of subsequent gastric metachronous lesions differed between the eradication group and the persistent infection group (OR = 2.322, 95% CI = 1.136-4.744, P = 0.021), and ≥60 age at the time of endoscopic resection (OR = 2.803, 95% CI = 1.207-6.509, P = 0.016). CONCLUSIONS: Both persistent H. pylori infection and old age (≥60) are independent risk factors for the increased incidence of metachronous gastric cancer.


Subject(s)
Gastric Mucosa/pathology , Helicobacter Infections/complications , Helicobacter pylori/isolation & purification , Stomach Neoplasms/pathology , Age Factors , Aged , Dissection/methods , Female , Follow-Up Studies , Gastroscopy/adverse effects , Helicobacter Infections/drug therapy , Humans , Incidence , Male , Middle Aged , Recurrence , Retrospective Studies , Risk Factors , Stomach Neoplasms/surgery
5.
Endoscopy ; 44(3): 293-6, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22354826

ABSTRACT

Endoscopic submucosal dissection (ESD) is safe and effective, but as the number of patients undergoing ESD has increased, so has the number of iatrogenic perforations. We describe the effectiveness and benefits of endoscopic mucosal resection after precutting (EMR-P) in a series of patients who developed a macroperforation during ESD. This was a retrospective, single-center case series from a prospectively maintained database in an academic tertiary care center. The study involved 16 patients with macroperforation out of 1171 patients who underwent ESD between November 2006 and January 2011. En bloc resection by EMR-P was achieved in 12 out of 16 patients (75%) and piecemeal resection in 4 (25%). All patients were discharged after a mean hospital stay of 6.8 days without further complications. There were no recurrences during the median follow-up period of 11.4 months. Macroperforation during ESD can be managed successfully by endoscopic closure, and EMR-P should then be considered.


Subject(s)
Adenocarcinoma/surgery , Dissection/adverse effects , Gastric Mucosa/surgery , Gastroscopy/methods , Stomach Neoplasms/surgery , Stomach/injuries , Adult , Aged , Female , Gastric Mucosa/pathology , Gastroscopy/adverse effects , Humans , Male , Middle Aged , Retrospective Studies , Stomach/pathology , Stomach/surgery
6.
Aliment Pharmacol Ther ; 35(1): 56-65, 2012 Jan.
Article in English | MEDLINE | ID: mdl-22066530

ABSTRACT

BACKGROUND: The eradication rates following standard triple therapy for Helicobacter pylori infection are declining worldwide. Recent studies have shown that sequential therapy for H. pylori infection yields high cure rates. AIM: To compare the efficacy and tolerability of a sequential regimen as first-line treatment of H. pylori infection with a standard triple regimen. METHODS: A total of 348 naïve H. pylori-infected patients from six hospitals in Korea were assigned randomly to standard triple or sequential therapy groups. Standard triple therapy consisted of 20 mg of rabeprazole, 1 g of amoxicillin and 500 mg of clarithromycin, twice daily for 7 days. Sequential therapy consisted of a 5-day dual therapy (20 mg of rabeprazole and 1 g of amoxicillin, twice daily) followed by a 5-day triple therapy (20 mg of rabeprazole, 500 mg of clarithromycin, and 500 mg of metronidazole, twice daily). RESULTS: The intention-to-treat (ITT) and per-protocol (PP) eradication rates were 62.2% (95% CI 54.8-69.6%) and 76.0% (95% CI 68.5-83.5%) in the standard triple group, and 77.8% (95% CI 71.4-84.2%) and 87.9% (95% CI 82.3-93.5%) in the sequential group, respectively. The eradication rate was significantly higher in the sequential group compared with the standard triple group in both the ITT and PP populations (P = 0.002 and P = 0.013 respectively), whereas the incidence of adverse events was similar. CONCLUSIONS: Ten-day sequential therapy is more effective and equally tolerated for eradication of H. pylori infection compared with standard triple therapy. Sequential therapy may have a role as first-line treatment for H. pylori infection.


Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Ulcer Agents/administration & dosage , Helicobacter Infections/drug therapy , Helicobacter pylori/isolation & purification , Peptic Ulcer/drug therapy , 2-Pyridinylmethylsulfinylbenzimidazoles/administration & dosage , 2-Pyridinylmethylsulfinylbenzimidazoles/adverse effects , Adult , Aged , Amoxicillin/administration & dosage , Amoxicillin/adverse effects , Anti-Bacterial Agents/adverse effects , Anti-Ulcer Agents/adverse effects , Clarithromycin/administration & dosage , Clarithromycin/adverse effects , Drug Administration Schedule , Drug Therapy, Combination , Endoscopy, Gastrointestinal , Female , Helicobacter Infections/microbiology , Humans , Male , Metronidazole/administration & dosage , Metronidazole/adverse effects , Middle Aged , Peptic Ulcer/microbiology , Rabeprazole , Republic of Korea , Time Factors , Treatment Outcome
7.
Eur J Gynaecol Oncol ; 32(1): 87-90, 2011.
Article in English | MEDLINE | ID: mdl-21446334

ABSTRACT

OBJECTIVE: To increase vigilance among gynecological surgeons for the presence of accessory polar renal artery (APRA) encountered with transperitoneal systemic laparoscopic paraaortic lymphadenectomy (LPAL). METHODS: A retrospective review was conducted on 156 women who underwent LPAL for various gynecologic malignancies between November 2003 and December 2009. RESULTS: The median age, parity, body mass index, and number of previous abdominal surgeries, respectively, of the women were 52 years (range, 23-82 years), two (range, 0-7), 24.1 kg/m2 (range, 17.4-35.0 kg/m2), and 0 (range, 0-3). During the study period, we found four women with APRA. There were three cases of right lower APRAs arising from the abdominal aorta, caudal to the inferior mesenteric artery (IMA), terminating at the parenchyma of the lower pole of the right kidney. In the other case, the APRA arose from the abdominal aorta superior to the IMA. There were no vascular complications, such as transection or ligation of the APRA. CONCLUSION: It is important for the gynecological oncologic surgeon to have knowledge of retroperitoneal vascular anatomy, experience in laparoscopic surgery, and an accurate surgical technique to avoid vascular injury during LPAL.


Subject(s)
Genital Neoplasms, Female/surgery , Laparoscopy/methods , Lymph Node Excision/methods , Peritoneum/surgery , Renal Artery/abnormalities , Adult , Female , Humans , Middle Aged , Retrospective Studies
9.
Endoscopy ; 42(8): 647-51, 2010 Aug.
Article in English | MEDLINE | ID: mdl-20669076

ABSTRACT

BACKGROUND AND STUDY AIMS: Rectal carcinoid tumors are often found incidentally during screening colonoscopy and can be resected using various endoscopic techniques. This study aimed to compare the safety and efficacy of endoscopic submucosal dissection (ESD) with endoscopic mucosal resection (EMR) for rectal carcinoid tumors. PATIENTS AND METHODS: Between January 2003 and June 2009, 74 patients (74 lesions) underwent either EMR (n = 28) or ESD (n = 46) for rectal carcinoid tumors. The rate of endoscopic complete resection, pathological complete resection, procedure complications, and tumor recurrence were analyzed retrospectively. RESULTS: The endoscopic complete resection rate was significantly higher in the ESD group (46 lesions, 100 %) compared with the EMR group (25 lesions, 89.3 %) ( P = 0.049). The pathological complete resection rate was higher in the ESD group (38 lesions, 82.6 %) compared with the EMR group (18 lesions, 64.3 %); however, this difference was borderline significant ( P = 0.067). Overall complication rate was not significantly different between the EMR group (3.6 %) and the ESD group (6.3 %). There was one case of remnant lesion in the EMR group, which was managed by ESD, and no recurrence has been detected in either the EMR or ESD groups. CONCLUSION: This study suggests that ESD might be a feasible treatment technique for small rectal carcinoid tumors. It showed superior efficacy and comparable safety to EMR.


Subject(s)
Carcinoid Tumor/surgery , Dissection/methods , Intestinal Mucosa/surgery , Proctoscopy/methods , Rectal Neoplasms/surgery , Adult , Carcinoid Tumor/pathology , Dissection/adverse effects , Female , Humans , Intestinal Mucosa/pathology , Male , Middle Aged , Proctoscopy/adverse effects , Rectal Neoplasms/pathology , Retrospective Studies , Treatment Outcome
10.
Ann Oncol ; 21(3): 525-529, 2010 Mar.
Article in English | MEDLINE | ID: mdl-19759184

ABSTRACT

BACKGROUND: The polymorphisms in DNA repair genes may contribute to a variation in the DNA repair capacity, thereby affecting the risk of carcinogenesis and prognosis of colorectal cancer. Accordingly, the present study analyzed 14 polymorphisms in DNA repair genes and their impact on the prognosis for patients with colorectal cancer. MATERIALS AND METHODS: Three hundred and ninety-seven consecutive patients with curatively resected colorectal adenocarcinoma were enrolled in the present study. The genomic DNA was extracted from fresh colorectal tissue and 14 polymorphisms of DNA repair genes determined using a real-time PCR genotyping assay. RESULTS: The median age of the patients was 63 years, and 218 (54.9%) patients had colon cancer, while 179 (45.1%) patients had rectal cancer. A multivariate survival analysis, including age, differentiation, carcinoembryonic antigen level, and stage, revealed a better survival for the patients with the combined IVS10+12AG and GG genotype than for the patients with the IVS10+12AA genotype [disease-free survival: hazard ratio (HR) 0.47, 95% confidence interval (CI) 0.30-0.75, P = 0.002; overall survival: HR 0.50, 95% CI 0.26-0.98, P = 0.042]. None of the other polymorphisms was associated with survival. CONCLUSION: The IVS10+12A>G polymorphism in the hMSH2 gene was found to be an independent prognostic marker for patients with colorectal cancer.


Subject(s)
Adenocarcinoma/genetics , Biomarkers, Tumor/genetics , Carcinoma, Signet Ring Cell/genetics , Colorectal Neoplasms/genetics , DNA Repair Enzymes/genetics , MutS Homolog 2 Protein/genetics , Polymorphism, Genetic/genetics , Adenocarcinoma/pathology , Adenocarcinoma/therapy , Adult , Aged , Aged, 80 and over , Carcinoma, Signet Ring Cell/pathology , Carcinoma, Signet Ring Cell/therapy , Colorectal Neoplasms/pathology , Colorectal Neoplasms/therapy , DNA Repair , Female , Genotype , Humans , Middle Aged , Neoplasm Recurrence, Local/genetics , Neoplasm Recurrence, Local/pathology , Neoplasm Recurrence, Local/therapy , Prognosis , Risk Factors , Survival Rate , Young Adult
11.
Endoscopy ; 41(9): 739-45, 2009 Sep.
Article in English | MEDLINE | ID: mdl-19693749

ABSTRACT

BACKGROUND AND STUDY AIMS: Discrepancies can occur between the histopathological findings from forceps biopsy and endoscopic mucosal resection (EMR), and occasionally in embarrassing cases tumorous tissue is not found at EMR. The aim of the present study was to evaluate the clinical, endoscopic, and histological features of gastric tumors in patients with pathololgically negative findings at EMR. PATIENTS AND METHODS: We retrospectively reviewed data from all patients with gastric tumor treated with EMR or endoscopic submucosal dissection (ESD) between August 1999 and April 2007 at our institution, and enrolled into the study patients with no tumor tissue found at mucosal resection. Their biopsy and EMR specimen slides were reviewed by a single pathologist. Patient characteristics, including demographic and clinical features, and the endoscopic appearance of mucosal lesions were evaluated. RESULTS: Out of 633 patients treated with EMR or ESD, 20 patients (3.2 %) were included. The mean +/- SD maximal dimension of the mucosal lesions was 6.40 +/- 2.19 mm (range 3 - 10). Mean number of forceps biopsy fragments was 3.80 +/- 1.96 and mean sampling ratio was 2.08 +/- 1.07 mm/fragment. Before resection, histological findings from forceps biopsy were: 13 low grade dysplasias (65.0 %), 2 high grade dysplasias (10.0 %), and 5 intramucosal carcinomas (25.0 %). CONCLUSIONS: In the case of pathologically negative findings at EMR, tumors might have been small enough to have been removed by the previous forceps biopsy. However, the possibility of sampling error or of a different location should be considered. Furthermore, appropriate communication between endoscopists and pathologists is essential.


Subject(s)
Diagnostic Errors , Endoscopy, Gastrointestinal , Gastric Mucosa/pathology , Stomach Neoplasms/pathology , Adenocarcinoma/microbiology , Adenocarcinoma/pathology , Adult , Aged , Biopsy , Dissection/methods , Endoscopy, Gastrointestinal/methods , Female , Gastric Mucosa/surgery , Helicobacter pylori/isolation & purification , Humans , Male , Middle Aged , Pyloric Antrum/pathology , Retrospective Studies , Stomach Neoplasms/microbiology
12.
Dig Liver Dis ; 40(5): 361-5, 2008 May.
Article in English | MEDLINE | ID: mdl-18291734

ABSTRACT

BACKGROUND/GOALS: Gastric dysplasia is believed to be the penultimate stage of gastric carcinogenesis. Few studies have evaluated whether there is a relationship between such risk factors and gastric dysplasia. This case-control study was conducted to investigate the associations between obesity, serum glucose, lipids and gastric dysplasia. STUDY: Endoscopic findings and pathology specimens were reviewed from 1 July 1997 to 31 December 2006 in the Health Promotion Center. One hundred thirty patients have the dysplasia in the stomach during screening endoscopy. The same number of controls was evaluated and matched to the gastric dysplasia group for age and gender. RESULT: The univariate analysis showed that the dysplasia risk was slightly increased among persons with a higher low-density lipoprotein, lower high-density lipoprotein, impaired fasting glucose and higher total cholesterol. However, a higher body mass index and higher triglyceride level were not associated with the diagnosis of gastric dysplasia. In the multivariate-adjusted model, a higher low-density lipoprotein cholesterol and glucose were strongly associated with an increased risk of dysplasia compared to the controls. However, the body mass index, triglyceride and total cholesterol were not associated with the risk for dysplasia. CONCLUSION: Hyperglycaemia and low-density lipoprotein cholesterol appear to be associated with the risk for gastric dysplasia. Further epidemiologic studies including a large cohort of patients with gastric dysplasia and adenocarcinoma are needed to clarify the association of low-density lipoprotein cholesterol, serum glucose and gastric carcinogenesis.


Subject(s)
Gastric Mucosa/pathology , Hypercholesterolemia/complications , Hyperglycemia/complications , Stomach Neoplasms/etiology , Biopsy , Blood Glucose/metabolism , Body Mass Index , Cholesterol, LDL/blood , Endoscopy, Gastrointestinal , Female , Follow-Up Studies , Humans , Hypercholesterolemia/blood , Hypercholesterolemia/epidemiology , Hyperglycemia/blood , Hyperglycemia/epidemiology , Incidence , Korea/epidemiology , Male , Middle Aged , Obesity/complications , Obesity/epidemiology , Precancerous Conditions , Prognosis , Retrospective Studies , Risk Factors , Stomach Neoplasms/epidemiology , Stomach Neoplasms/pathology
13.
Endoscopy ; 40(1): 7-10, 2008 Jan.
Article in English | MEDLINE | ID: mdl-18210339

ABSTRACT

BACKGROUND AND AIM: Endoscopic mucosal resection (EMR) is currently not accepted as an alternative treatment to surgery in early gastric cancer (EGC) of the undifferentiated histologic type. The present retrospective analysis examined the correlation of various histologic factors with the presence of lymph node metastasis (LNM). PATIENTS AND METHODS: A retrospective analysis on 234 patients with poorly differentiated EGC who underwent radical gastrectomy with D2 lymph node dissection was undertaken. Several clinicopathologic factors were investigated to identify predictive factors for LNM: age, sex, type of operation, tumor location, tumor size, gross type, ulceration, lymphatic invasion, and depth of invasion. RESULTS: Of the 234 lesions with poorly differentiated EGC, half (n = 116) already showed submucosal invasion in the resection specimen; 25.9 % of those (30/116) were limited to the upper third (SM1). Of the lesions confined to the mucosa, LNM was found in 3.4 % (4/118). With minor submucosal infiltration (SM1), the LNM rate was lower (0/30) in our patient population. Only with SM2/3 infiltration did the LNM rate sharply rise to around 30 %. The cut-off for submucosal infiltration depth was 500 microm (0/32 LNM), above which LNM rates were substantial (31.2 %; 24/77). There was limited correlation between the SM1-3 classification and actual measurement of submucosal infiltration depth. In a multivariate analysis, tumor size ( P = 0.033), depth of invasion ( P = 0.004), and lymphatic invasion ( P < 0.001) were associated with LNM. CONCLUSION: Poorly differentiated EGC confined to the mucosa or with minimal submucosal infiltration (

Subject(s)
Adenocarcinoma/secondary , Adenocarcinoma/surgery , Gastroscopy/methods , Lymph Node Excision/methods , Stomach Neoplasms/pathology , Stomach Neoplasms/surgery , Adenocarcinoma/mortality , Adult , Age Factors , Aged , Aged, 80 and over , Endoscopy/methods , Feasibility Studies , Female , Gastrectomy/methods , Gastric Mucosa/pathology , Gastric Mucosa/surgery , Humans , Korea , Logistic Models , Lymphatic Metastasis , Male , Middle Aged , Multivariate Analysis , Neoplasm Staging , Predictive Value of Tests , Probability , Retrospective Studies , Risk Factors , Sex Factors , Stomach Neoplasms/mortality , Survival Analysis , Treatment Outcome
14.
Int J Clin Pract ; 61(5): 802-9, 2007 May.
Article in English | MEDLINE | ID: mdl-17343665

ABSTRACT

This study aimed to analyse the characteristics of adrenal masses visible in the computerised tomography (CT) scans which have been also evaluated by 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography (18F-FDG PET), and to characterise the features of 18F-FDG PET scans associated with various adrenal endocrine tumours, especially benign functional tumours. 18F-FDG PET scans of 105 patients with adrenal masses on the CT scan were analysed. Positive uptakes in the 18F-FDG PET scans were seen in 60 malignant tumours (54 metastasic lesions, six primary adrenal cancers) and seven benign tumours. The positive predictive value of 18F-FDG PET imaging to characterise an adrenal mass as a malignant tumour was 90%; the corresponding negative predictive value to rule out malignancy was also 90%. Benign adrenal tumours were smaller than that of malignant lesions (p<0.05). The mean standardised uptake value max (SUVmax) of the metastatic lesions [8.4+/-6.5 (microCi/g)/microCi/kg] was significantly higher than that of the benign adrenal tumours [2.4+/-1.2 (microCi/g)/microCi/kg, p<0.001]. Examination of only the primary adrenal lesions revealed that all adrenocortical carcinomas, two of three cases of pheochromocytomas, three of five neuroblastomas and two of four cases of primary aldosteronism showed positive 18F-FDG uptake. In conclusion, for patients presenting adrenal masses with a high probability of malignancy, 18F-FDG PET can be used to differentiate malignant from benign adrenal lesions. However, the 18F-FDG PET uptake did not show an always consistent pattern for endocrine tumours, which was probably due to the variability inherent in 18F-FDG uptake. This study suggests that 18F-FDG PET scanning can offer supporting data to localise and characterise adrenal tumours.


Subject(s)
Adrenal Gland Neoplasms/diagnostic imaging , Fluorodeoxyglucose F18 , Positron-Emission Tomography/methods , Radiopharmaceuticals , Adrenal Gland Neoplasms/pathology , Adrenal Gland Neoplasms/secondary , Adult , Child, Preschool , Female , Humans , Infant , Male , Middle Aged
SELECTION OF CITATIONS
SEARCH DETAIL
...